<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220063</url>
  </required_header>
  <id_info>
    <org_study_id>06/9-R</org_study_id>
    <nct_id>NCT01220063</nct_id>
  </id_info>
  <brief_title>RSHF in Colorectal Cancer</brief_title>
  <acronym>RS CAMPTO</acronym>
  <official_title>CLINICAL MULTICENTER STUDY OF PHASE II AND RADIOBIOLOGY ASSESSING Hypofractionated Stereotactic Radiotherapy With Irinotecan (Campto) IN THE TREATMENT OF LIVER METASTASIS AND / OR PULMONARY, Unoperated or Recurrent After Surgery of a Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4
      fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation
      session).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2007</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response accoording to recist criteria</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation + Irinotecan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Irinotecan will be administered :
- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy
Radiotherapy (RSHF) will be administered :
at D1, D3, D8 and D10
48 Gy, 12 Gy by fractions twice a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>10 Gy for 4 times (total 40 Gy)</description>
    <arm_group_label>Radiation + Irinotecan</arm_group_label>
    <other_name>RSHF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>40 mg/m² : Day 1 and day 8</description>
    <arm_group_label>Radiation + Irinotecan</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years

          -  Social Insurance

          -  Performance Index &lt;2

          -  Life expectancy&gt; 6 months

          -  adenocarcinoma colorectal (histologically proven)

          -  Metastases (inoperable or recurrent after surgery),

          -  hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if
             the two bodies are metastatic). The largest diameter of the metastasis will &lt; ou = 6cm
             for the liver, &lt; or = 6 cm for the lung. If multiple metastases, the sum of their
             maximum diameter is 6cm &lt; ou = the liver, &lt; ou = 6 cm for the lung.

          -  Lesion (s) measurable (s) and evaluable (s)

          -  CT less than 3 weeks

          -  Patients must have received at least one prior chemotherapy regimen containing 5FU

             • Patients may have received one or more lines of chemotherapy including irinotecan.

          -  bilirubin &lt;1.5 x ULN

          -  AST and ALT &lt;5x ULN

          -  neutrophils&gt; 1.5x109 / L, platelets&gt; 100x109 / L, hemoglobin&gt; 9 g / dL

          -  TP, TCA Normal (only for patients treated with a permanent implant)

          -  Informed consent signed.

        Exclusion Criteria:

          -  contraindication to the administration of irinotecan.

          -  History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation.

          -  History of other invasive cancer treated in a period of less than 5 years (basal cell
             carcinoma and non-invasive cervical excepted)

          -  Metastatic disease diffuse or more than three metastases in the liver and / or lung
             during the natural history of disease (excluding any patient is having a complete
             radiological response on several metastases although 1-3 residual after treatment ( s)
             medical (at)).

          -  Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the
             cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left
             pulmonary arteries and right and left.

          -  Pregnancy or breastfeeding.

             - Lack of means or refusal to use effective contraception for men or women of
             childbearing age.

          -  Any other concomitant experimental treatment.

          -  Any other concurrent anticancer therapy, immunotherapy or hormonal therapy.

          -  Monitoring impossible because of psychological, sociological or because of
             geographical distance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RIO EMMANUEL, MD</last_name>
    <role>Study Director</role>
    <affiliation>INSTITUT DE CANCEROLOGIE DE L'OUEST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la Source</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSHF</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

